ABSTRACT
Introduction
Since its discovery as an antitumor agent, cisplatin or cisdiamminedichloroplatinum(II) (abbreviated herein as Pt II ), has been applied in the treatment of various solid tumors (e.g., ovarian and testicular cancer, germ cell tumors, and non-small-cell carcinoma) with a cure rate as high as 90 % for testicular cancer. [ [1] [2] [3] [4] [5] [6] ] When entering tumor cells, the active Pt II drug reacts with DNA to form adducts, inhibits its replication and triggers apoptosis (programmed cell death). The synergistic combination of Pt II and ionizing radiation induces additional damage to DNA, and degrades cell viability through formation of toxic Pt intermediates and inhibition of the DNA repair process [ 4 ] .
However, clinical use of Pt II is limited by severe side effects and poor patient compliance. [ 7 ] Indiscriminate uptake of the drug into both normal and cancerous tissue, coupled with rapid clearance and excretion through the kidney, limits the achievable dose delivered to tumor cells. [ 8 ] Despite these issues, cisplatin continues to serve as a first-line chemotherapy against specific malignancies and has been described as the "gold standard" treatment for cervical cancer. [ 9, 10 ] In this context, nanoparticle (NP)-based drug delivery systems are a promising approach to improve targeting and enable high delivered doses, while minimizing the toxic side-effects to healthy tissue. [ 11, 12 ] Use of NP delivery platforms may enhance the accumulation of the drug in tumors, minimizing either kidney excretion or uptake by healthy cells, via the well-documented enhanced permeation and retention (EPR) effect.
[ 13, 14 ] In other words, by attaching the drug to NPs, the physicochemical properties of the resulting complex are changed, leading to altered pharmacokinetics and biodistribution profiles. NPs can also be engineered through interfacial chemistry to serve multiple functions in addition to drug delivery (e.g., active and passive targeting, avoidance of the reticuloendothelial system, reduced interaction with plasma proteins, imaging of localized drug delivery.
[ [15] [16] [17] [18] [19] For instance, AuNPs have been used as a platform for drug delivery, due in part to their biocompatibility, facile synthesis and functionalization, and physico-chemical stability.
[ [20] [21] [22] ] Cytotoxicity in both lung epithelial and colon cancer cell lines, and an importance. An optimal design should afford rational control facilitated by an understanding of the underlying surface properties in order to achieve the desired outcome. To support a quality by design approach, it is also necessary to have measurement tools required to accurately assess the critical physical and chemical quality attributes of the nano-drug complex, as well to quantify drug uptake and release.
This paper describes and demonstrates such a strategy based principally on coupling of an aerosol-based ion mobility technique with plasma-based mass spectrometry. As we will show, this strategy provides critical information and insight regarding the efficacy of surface engineering in the tested system.
In the current study, we chose as our test bed a functional dendron structure, designated SH-G1-COOH (inset in Figure 1 ), which in our previous study exhibited the maximum available surface binding sites, but also the poorest colloidal stability.
[
]
The AuNP surface was modified with polyethyleneglycol (PEG) for the purpose of improving colloidal stability through additional steric hindrance. In addition,
PEGylation has been shown to enhance biocompatibility and delay clearance, [ [28] [29] [30] though quantifying these effects was beyond the scope of this study. The present work investigates the effect of surface PEGylation on colloidal stability, drug loading and release performance using the test bed formulation.
An electrospray differential mobility analyzer hyphenated with inductively coupled plasma mass spectrometry (ES-DMA-ICP-MS) or a condensation particle counter (CPC), as described in a previous publication, 
Experimental

Materials.
Citrate stabilized gold colloid (10 nm nominal particle diameter) was obtained from ). G1 expresses a branched structure analogous to a 1 st generation dendrimer terminated with three COOH groups. SH-G1-COOH has a wedge-shaped branching structure as shown in Figure 1 . The COOH groups provide complexing sites for Pt II , and the thiol group provides covalent bonding to the AuNP surface. To activate (deprotonate) the carboxylate group, the dendron (5 mmol/L) was dissolved in NaOH (15 mmol/L) to obtain the maximum carboxylate population.
Conjugation of AuNP-(dendron) and AuNP-(dendron)-(SH-PEG)
As illustrated in Figure 1 is shorthand for SH-PEG5K in all the figures, and similarly for 1K and 10K.
After reaction, the mixture was again purified by centrifugal filtration, at 4000 rpm The effect of reaction time on Pt II complexation was also examined (SI Figure   S1 (b)), based on which a 2 h reaction time was deemed sufficient, as no significant increase in Pt II loading was observed over longer reaction times. 
Cisplatin release
Uncomplexed Pt II was first removed from samples using two rounds of cleaning via centrifugation in a microfuge and supernatant replacement by DI water. Pt II release studies were carried out by ICP-MS measurement of free Pt II at time points of (0, 2 and 10) day, after separating free (released) Pt II from AuNP-bound Pt II using centrifugal filtration (3 kDa regenerated cellulose membrane 
Measurements
ES-DMA-ICP-MS (CPC)
The schematic of the instrumentation as shown in Figure size so that an elemental characterization as a function of particle size could be obtained. Pt (see SI Figure S2 (a)-(b)). 
ATR-FTIR
ATR-FTIR spectra were collected on a Thermo Scientific Nicolet iS50 (Thermo 
Results and Discussion:
Molecular conjugation of dendron and SH-PEG on AuNPs
SH-PEG with three molar masses (1 kDa, 5 kDa and 10 kDa) were examined. Table S1 . For clarity, the number densities shown in Figure 3 for the ATR-FTIR study. Baseline subtraction was performed for each spectrum (adsorption at wavenumber 1800 nm -1 was chosen as zero) and followed by normalization to the highest peak intensity.
Dashed lines mark the characteristic vibrational modes from dendron (COO -, C=O) and SH-PEG5K (C-O).
To better understand the adsorption, and to examine dendron binding and possible steric hindrance due to SH-PEG, we quantify the extent of SH-PEG adsorption on the dendron conjugated AuNP using a refined two-layer geometric model. Prior work has demonstrated the capacity to quantify ligand surface packing density based on careful PSD measurements using ES-DMA.
The general concept of this analysis is that by assuming a random coil configuration for the linear SH-PEG molecule, the surface coverage of SH-PEG is obtained from the increase in cross-sectional area obtained via DMA. In the present study, we refine the core-shell model used previously to account for two ligand layers, as the contributions to particle size from either ligand cannot be neglected (Figure 4(a) ).
In the two-layer model, the net contribution of SH-PEG to the increase of crosssectional area was obtained by subtracting the cross-section increase due to the dendron from the total increase. The cross-sectional area of the SH-PEG corona is a function of particle diameter, and therefore the packing density (σ in unit of molecules/nm 2 ) of SH-PEG can be correlated with changes in particle diameter. [ 34, 38 ] :
where <x 2 > 0.5 is the random walk radius, the calculated value of which is 3. AuNPs is attributed to intermolecular steric hindrance between the SH-PEG molecules when more closely packed on the surface. Note that the higher relative molar mass of SH-PEG10K yields a higher occupied area per molecule on the AuNP surface, and therefore a lower molecular packing density.
We may conclude for this part of the study that the principal limiting factor for uptake of SH-PEG by the AuNP-dendron conjugate is the availability of bonding sites or open surface (due to pre-attached dendron) and apparently not a result of steric hindrance, which would increase with molar mass of SH-PEG. 
Binding of cisplatin to surface engineered AuNPs
In the next phase of this investigation, we evaluate the effects of Pt II complexation on conjugated AuNPs and, conversely, the effects of surface engineering on Pt II complexation. Figure 5(a) shows the element-mass weighted particle size distribution In combination with the quantification of dendron and SH-PEG obtained in Figure 4 and Figure 5 , we conclude that attachment of SH-PEG does not significantly degrade the loading capacity for the active drug. This insensitivity is likely due to the low PEG adsorption density observed. Pt II loading vs SH-PEG molar mass (1kDa, 5kDa and 10kDa), at around saturation packing density (i.e.
5 to 1 dendron to SH-PEG ) at CPt II = 11.4 µmol/L. Error bars for σPt II represent one standard deviation about the mean value derived from Pt/Au across a range of particle sizes in the mass-based PSD for one measurement in the same sub-sample. Uncertainties for same subsample (but with measurement replicates) and between different samples are based on relative standard deviation and averaged < 9 %, demonstrating good precision and sample-to-sample reproducibility (for details see SI Figure S4 ).
Colloidal stability (by ES-DMA-ICP-MS)
Previous work has shown that complexation of Pt II itself leads to colloidal destabilization of the conjugate due to electrostatic interactions between the anionic carboxylates and the positively charged Pt Therefore, the number of oligomer particles is related to the 197 Au intensity as follows:
where Ψ represents a function that includes the sensitivity factor for 197 Au, αAu, and the density and volume of a primary size AuNP, ρAu and VAu (i.e., Ψ = f ( αAu, ρAu, VAu)). N,n represents the number of nanoparticle agglomerates containing n primary particles. It should be noted that for a given set of experimental conditions, Ψ is a constant and not a function of the oligomer state.
In order to investigate the colloidal stability of nanoparticles, we utilize the degree of agglomeration (DA). The degree of agglomeration is defined here as follows:
Combining with equation (4), DA is expressed as:
Therefore, DA represents the average number of particles per agglomerate and will increase from unity with respect to time for an unstable system. Considering the resolving power of ES-DMA-ICP-MS to distinguish oligomers, the present analysis is limited to tetramers, and therefore the maximum DA in this study is four. As an example, at day 10, AuNP-(dendron) provides an opportunity to surface engineer further improvements in the release performance in conjunction with the demonstrated improvements in stability due to PEG; however, this was beyond the scope of the present study. 
Summary and Conclusions
In this study, we built upon previous efforts that established the capacity for a novel hyphenated technique, ES-DMA-ICP-MS, to examine, on a quantitative basis, the effects of surface engineering on drug loading and colloidal stability for a model nanoscale anti-tumor drug delivery platform. 
